Midodrine or atomoxetine pill

PreclinicalSmall molecule

Midodrine or atomoxetine pill is one of 6 small molecule programs targeting Orthostatic Hypotension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic HypotensionActive, not recruiting

Orthostatic; Hypotension, NeurogenicRecruiting

Orthostatic HypotensionPreclinical

Active, not recruiting

Orthostatic; Hypotension, NeurogenicPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Orthostatic Hypotension

#DrugCompanyPhaseTrials

Northera

Lundbeck

Approved

10 2

Proamatine

Takeda

Approved

7 3

Corlanor

Amgen

Approved

—4

Inderal

WWyeth-Lederle Vaccines

Mestinon

1 6

Midodrine or atomoxetine pill

VVanderbilt University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Orthostatic; Hypotension, Neurogenic

NCT04782830

Clinical

Trials by Indication[1]

Orthostatic; Hypotension, Neurogenic1 trial

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

Recruiting·VVanderbilt University Medical Center·Preclinical·NCT04782830·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Midodrine or atomoxetine pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Midodrine or atomoxetine pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Midodrine or atomoxetine pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University Medical Center

Midodrine or atomoxetine pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Orthostatic; Hypotension, Neurogenic1 trial

References

Drug Info

Quick Facts

Related News